Repertoire Immune Medicines   Report issue

For profit Phase 1
Founded: Cambridge MA United States (2017)

Organization Overview

First Clinical Trial
2021
NCT04762225
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Repertoire Immune Medicines

Active Ingredients

Drugs in Phase 1 Trials (2)

Key: Repertoire Immune Medicines (1) Acquired (1)

rptr-168 (1 trial)

trq15-01 (1 trial)

Indications

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2